In the News: CoQ10 Linked to Better Liver Enzyme Levels

 Ultraprocessed foods boost cancer risk; CoQ10 improves liver enzyme levels; glucosamine reduces risk of vascular dementia; higher B12 levels linked to lower inflammation.

Scientifically reviewed by Amanda Martin, DC, in March 2024.

Eating Ultraprocessed Foods Increases Risk of Cancer and Other Diseases

A review and meta-analysis of randomized clinical trials concluded that coenzyme Q10 (CoQ10) was significantly associated with better, reduced levels of the liver enzymes: alanine aminotransferase (ALT), aspartate aminotransferase (AST) and gamma-glutamyl transferase (GGT).* These enzymes are often elevated in people with liver disorders.

The researchers analyzed the find- ings of 15 randomized, controlled trials that administered CoQ10 and reported changes in liver enzymes.

Participants included a total of 712 men and women with conditions such as coronary heart disease, type I or type II diabetes, nonalcoholic fatty liver disease or elevated lipids.

CoQ10 supplemented participants had beneficial reductions in elevated liver enzymes.

Editor’s Note: Coenzyme Q10 doses ranged from 100 to 400 mg per day consumed for two to 24 weeks.

* Food Sci Nutr. 2023 Jun 7;11(9):4912-4925.

Higher B12 Levels Associated with Less Inflammation

Researchers uncovered a link between higher serum vitamin B12 levels and lower levels of C-reactive protein (CRP) and interleukin-6 (IL-6), which increase during inflammation.*

The study utilized data from a sub- group of 136 participants in the PREDIMED trial who had available data concerning their serum con- centrations of vitamin B12 and CRP, and plasma IL-6. The PREDIMED trial was designed to evaluate the relationship between consuming a Mediterranean diet and cardiovas- cular disease prevention.

Men and women who had higher vitamin B12 levels had lower con- centrations of CRP and IL-6. Similar findings were obtained when the researchers measured these factors in aged mice.

Editor's Note: "Since chronic inflammation is associated with a wide range of diseases, understanding how vitamin B12 status influ- ences inflammation could have significant implications for disease prevention and management," the authors noted.

* J Sci Food Agric. 2024 Jan 30;104(2): 875-882.

Glucosamine May Also be Beneficial Against Vascular Dementia

People with osteoarthritis who used glucosamine, a compound that supports joint health, were also at reduced risk of developing vascu- lar dementia, according to a study published in Alzheimer’s Research and Therapy.*

Participants included 214,945 men and women in the UK Biobank, over the age of 60, who did not have dementia at baseline. Their question- naire responses provided informa- tion concerning regularly consumed nutrients. During a median 12-year follow-up, 1,039 individuals developed vascular dementia, 1,774 developed Alzheimer’s disease and 122 developed frontotemporal dementia.

Habitual use of glucosamine was associated with an 18% lower risk of vascular dementia compared with non-use. People who additionally consumed calcium had a 54% lower risk of vascular dementia than those who did not use glucosamine. No association was observed between glucosamine and the development of Alzheimer’s disease or frontotemporal dementia.

Editor’s Note: “If further confirmed, habitual glucosamine use may act as a dietary supplement for primary prevention of vascular dementia in the elderly,” the authors stated.

* Alzheimers Res Ther. 2023 Sep 9;15(1):152.

Eating Ultraprocessed Foods Increases Risk of Cancer and Other Diseases

Consuming ultraprocessed food increases the risk of cancers of the upper digestive tract, which includes mouth, throat, and esophageal cancers, according to a study published recently in the European Journal of Nutrition1 and reported on by CNN and other news media.

Ultraprocessed foods include soda, chips, instant soups, cookies, ice cream, cereal bars, and many others that include ingredients you wouldn’t use in a regular kitchen.

These additives are designed to resist mold and bacteria and to keep ingredients from separating. They also include bulking and bleaching agents, artificial dyes, or added salt and sugar to make the product more appealing.

Participants included 450,111 adults in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. They were recruited from 1992 to 1999 from 10 different European countries and the United Kingdom.

Results showed that people who consumed just 10% more ultra- processed foods than others in the study had a:

• 23% higher risk of head and neck cancers, and a
• 24% increased risk of esopha- geal cancer.

These data were collected in the 1990s, when consumption of ultra-processed food was much lower than it is now, and so the link to health risks is even higher today.

Indeed, as of 2019, ultraprocessed food made up approximately 71% of the food supply in the United States.2

Many studies over the past two years have demonstrated the alarm- ing link between ultraprocessed foods and cancer and other serious health problems. Here are a few examples of the findings:

• Men who consume ultraprocessed food have a higher risk of colorectal cancer, heart disease, and early death.3
• For every 10% increase in ultraprocessed food, there is a 2% increase in developing any kind of cancer, and a 19% increased risk of ovarian cancer.4
• Eating higher amounts of ultra- processed animal foods and sweetened beverages increases the risk of having multiple chronic conditions like cancer, diabetes, and heart disease.5
• Consuming more ultraprocessed foods is connected to depression in women.6
• Consuming about 20% of daily calories in ultraprocessed foods is linked to 28% increased risk of dementia.7

In the most recent study, researchers dug deeper to determine if excess weight accounted for the increased cancer risk.

Ultraprocessed foods are calorie dense and can contribute to obesity, and being obese or overweight is connected to an increased risk of 13 different types of cancer.

However, results showed that weight alone did not account for the increased cancer risk. Increased hip-to-weight ratio accounted for 5% of the 23% increased risk of head and neck cancer.

And increased body mass index (BMI) accounted for 13% of the 24% increased risk of esophageal cancer.

This indicates that factors other than obesity contribute to the increased cancer risk.

Editor’s Note: According to a large number of recent studies, ultraprocessed foods are associated with an increased risk of cancer, heart disease, dementia, and more.

References

1. Eur J Nutr. 2023 Nov 22.
2. Nutrients. 2019 Jul 24;11(8).
3. BMJ. 2022;378:e068921.
4. EClinicalMedicine. 2023 Feb;56:101840.
5. The Lancet Regional Health.2023;0(0):100771.
6. JAMA Netw Open. 2023 Sep 5;6(9):e2334770.
7. JAMA Neurol. 2023 Feb 1;80(2):142-50.

https://www.lifeextension.com/magazine/2024/3/coq10-linked-to-better-liver-enzyme-levels-in-the-news

Issues with the Ketogenic Diet

WHAT YOU NEED TO KNOW

Boost Ketones Without a Risky Diet

• Ketones are compounds produced by the liver during times of fasting or extremely low carbohydrate intake.
• Ketones are used as an alternative fuel by the brain and muscles. They also activate pathways linked to lifespan and health-span extension.
• The ketogenic diet stimulates ketone production but requires extremely high fat intake that has harmful health consequences.
• Safer alternatives directly supply ketones that can be absorbed and used by the body. Beta-hydroxybutyrate regulates energy expenditure and helps modulate metabolism. Mangiferin and a resistant starch also boost the body’s ability to make its own ketones.
• It is now possible to obtain the benefits of ketones without the difficulties and downsides associated with prolonged fasting or the ketogenic diet.

Issue: Oct 2019

Healthy Way to Benefit from Ketones

The low carb/high fat ketogenic diet has become a popular way to lose weight. But ingesting bad fats increases cardiovascular risks. Scientists have identified a healthy method to increase ketones without the difficulties of a ketogenic diet.

Issues with the Ketogenic Diet

One way to raise ketone levels is by forcing the body to create more of them. That’s the goal of the popular ketogenic diet. Severely restricting carbohydrate intake and replacing those calories with a large amount of fat makes the liver pump out ketones.

But there are several downsides to this strategy:

• Eliminating carbs means dramatically reducing intake of fruits, vegetables, and whole grains. These foods are a source of dietary fiber, which is critical for digestive health. Insufficient fiber has been linked to gastrointestinal disorders and colorectal cancer.17,18
• Very low carbohydrate intake has been linked to premature mortality.11
• A high-fat diet can cause elevated triglycerides, other lipid abnormalities, and detrimental metabolic changes, all risk factors for cardiovascular disease.10,19
• In people on a ketogenic diet, the risk of atherosclerotic plaque development in arteries, which often leads to cardiovascular disease, may be increased.9
• High-fat, low-carb diets can negate or even reverse the brain benefits of ketones, leading to deterioration in attention, processing speed, and mood.10

In other words, the potential problems of the ketogenic diet may outweigh the benefits. It is not recommended for people unless they have a specific medical condition for which it is indicated.

Raise Ketones the Healthy Way

Scientists recently set out to create a healthier way to raise ketone levels without the risks of the ketogenic diet or prolonged fasting.

They accomplished this by combining the ketone beta-hydroxybutyrate with two other nutrients that aid in the body’s ketone production.

When ingested orally, beta-hydroxybutyrate is easily absorbed into the bloodstream, providing the same benefits as ketones produced by the liver. Beta-hydroxybutyrate can increase blood levels to the range typically induced by a ketogenic diet.20

Mangiferin is a compound found in plants, especially mangos—hence the name. It has been shown to help spur the production of more ketones by the body.

In one randomized trial, researchers demonstrated that 150 mg of mangiferin per day significantly increased blood levels of ketones, presumably by stimulating the liver to boost production of them.21

In response to mangiferin supplementation, beta-hydroxybutyrate increased by about 18% and acetoacetate levels increased by approximately 10%.

A resistant starch, like cassava, is a complex carbohydrate that is not efficiently broken down by our digestive enzymes.22

Benefits of “Resistant Starch”

Other forms of starch are broken down into simpler carbohydrates, which raise blood sugar levels after a meal, triggering insulin secretion.

Because they are not digested rapidly by humans, resistant starches do not raise blood glucose or cause an insulin response.

Besides being a source of fiber, resistant starches have several other beneficial effects. They help support healthy gut bacterial growth, promote a feeling of fullness, increase insulin sensitivity, and preserve lean body mass.23

Resistant starches also enhance the body’s production of butyrate, which is used to make more ketones, and to stimulate many of the same longevity-promoting pathways as ketones.5,24,25

https://www.lifeextension.com/magazine/2019/10/healthy-way-to-benefit-from-ketones

Curcumin Starves Cancer Cells to Death - by Life Extension

Cancer cells require tremendous energy to promote their rapid growth. A new study shows how curcumin can selectively starve tumor cells.

Winter 2018-2019 Special Edition

By Kirk Stokel

(Previously published here on 7 October 2019)

Over 4,500 published studies describe the anti-cancer effects of curcumin.

Researchers are intrigued by a promising discovery that curcumin selectively starves tumor cells to death.1

Curcumin does this by depriving cancer cells of the ability to make and use ATP, the energy currency within cells.2

Since most cancer cells generate ATP in a different way than healthy cells, curcumin selectively kills tumor cells with no impact on healthy tissues.

These newly uncovered energy-disrupting properties of curcumin further support the preventive potential of this botanical compound.

Cutting Cancer’s Energy Supply

Cancer cells require tremendous energy to promote their rapid, uncontrolled growth, and they have developed numerous methods to support that energy demand.

In particular, cancer cells have an unusual, oxygen-free mechanism of extracting energy from glucose to produce ATP (adenosine triphosphate). This process helps most cancer cells survive in the low-oxygen environments they generate as they grow rapidly.2

Scientists conducted a study to determine if this process can be reversed in cancer cells.

Since many different types of cancer use the same metabolic trick to extract energy, the researchers studied curcumin’s impact on a variety of tumor lines, including leukemia, breast, melanoma (skin), and colon cancers.2

This study shed new light on curcumin’s ability to starve cancer into submission by interfering with how tumors cells use energy.

Let’s look at the findings one at a time.

Curcumin Blocks ATP Production

First, the researchers found that curcumin can sharply reduce how much energy is available to the cancer cells.2

This study showed that curcumin was able to:

1) Reduce levels of ATP-synthase (the enzyme that creates ATP) in all four tumor cell lines in culture,

2) Reduce cellular levels of ATP in three of the four cell lines, and

3) Lower the ratio of high-energy ATP to lower-energy AMP in all four cell lines.

Curcumin Slows Tumor Growth

Next, researchers implanted aggressive skin cancer (melanoma) cells into live mice. Half the mice were treated with curcumin and the other half served as the control group.2

Just 2 days into the study, the curcumin-treated mice were demonstrating significantly slower tumor growth. Tumor growth remained significantly slower for the entire period of the study.

Not surprisingly, ATP-synthase, ATP levels, and the ATP/AMP ratio were all significantly lowered in the curcumin group. These results indicate that energy starvation was a mechanism of action by which curcumin slowed tumor growth.

Curcumin Prevents New Blood Vessel Growth

Cancers need to trigger new blood vessel development (called angiogenesis) to support their nutrient needs as they rapidly grow. Blocking this process is an important way to limit the growth and spread of a tumor.

After removing tumors from the mice in this study, the researchers found that the curcumin-supplemented animals’ tumors had fewer new blood vessels compared with control-fed mice.

This indicates that curcumin reduced the tumors nutrient energy access by limiting blood flow.2

Curcumin’s Known Tumor-Fighting Properties

This most recent study adds to an abundance of evidence pointing to curcumin’s potent cancer-fighting abilities. It focuses on curcumin’s unique ability to combat a variety of cancers by cutting off their energy supply.

Previous studies have shown curcumin’s tumor-fighting properties in multiple specific types of cancer. Here are some highlights from the most recent literature.

Colorectal Cancer

Cancers of the colon and rectum are among the most common malignancies in men and women. Curcumin has a long track record of achievements in preventing colorectal cancers.

A Phase IIa human clinical trial has shown that 4 grams/day of curcumin significantly reduces the number of aberrant crypt foci found during endoscopy. This is a critical finding because if aberrant crypt foci are left untreated, they can produce malignant tumors.3

Weight loss is common in cancer patients. A human study showed that colon cancer patients who were supplemented with curcumin gained more weight, had less inflammation, and had increased numbers of cancer cells dying by apoptosis.4 This effect has been traced to curcumin’s ability to activate a “programmed cell death” gene in tumor cells.

Finally, curcumin has been shown to selectively reduce the survival of cancer stem cells.5 These cells account for much of the metastatic spread and tumor recurrences seen in aggressive malignancies. Cutting their numbers is an appealing approach to preventing tumors from spreading.

While a high-dose (4,000 mg) of curcumin was used in this study, more bioavailable curcumin forms can enable one to achieve a similar dose with two capsules a day.

WHAT YOU NEED TO KNOW

Curcumin Starves Cancer Cells to Death

• Curcumin is a powerful, multi-functional polyphenol that is gaining increasing recognition for its cancer chemopreventive properties.
• A new study shows that curcumin sharply restricts cancer cells’ ability to extract energy from glucose in the blood.
• This mechanism is especially appealing for cancer chemoprevention because it would target the great majority of cancers.
• Previous studies also show that curcumin can reduce inflammation, prevent chemical stress, shut down cancer-promoting pathways, and interfere with malignant cells’ growth and development.
• These multiple mechanisms of action make it clear that curcumin should be a central element of any comprehensive cancer chemoprevention regimen.

Breast Cancer

Breast cancer is the most common cancer in women, and it’s the second leading cause of cancer deaths among women worldwide.6,7

Curcumin has shown promise in combatting breast cancer. This is especially true of estrogen receptor-negative tumors, which respond poorly to cancer chemotherapy.6

Studies show that giving curcumin to animals with implanted human breast cancers shrinks the tumors, deprives them of their blood supply, and triggers their self-destruction by apoptosis.6,8

More recently, research revealed that curcumin can also combat breast cancer by reversing the excessive methylation of certain genes that is associated with increased cancer development.9

Prostate Cancer

Prostate cancer strikes one in nine American men, yet is among the most preventable cancers because of its slow growth.10

Curcumin has multiple actions against prostate cancer. It defends prostate cells against the dysfunctional proteins produced during cancer progression. It also slows invasion of nearby healthy tissue by the cancer, which helps to keep the tumor at a lower grade (meaning it grows more slowly and has a better prognosis).11-13

One study showed that when human prostate cells were implanted into mice, they grew into sizable tumors. But when these animals were supplemented with curcumin, the tumors grew 27% more slowly. In addition, the time it took to double levels of prostate specific antigen (PSA) was extended or delayed by about two-fold.14 (Doubling time is an indicator of how aggressive the cancer is.)

Curcumin can also reduce tumor-derived testosterone production in prostate cancer cells.15 This is a hidden source of male hormones that often contributes to treatment-resistant disease.16 This development offers a welcome new approach to treating these challenging tumors.

Liver Cancer

Liver cancer is increasing in incidence worldwide, spurred by epidemic hepatitis C virus and rampant fatty liver disease.17 

In lab studies, curcumin was shown to help prevent liver cancer by reducing inflammatory signaling, inhibiting cell growth, and activating cell death by apoptosis.18-20 It has also been shown to reduce populations of liver cancer stem cells.19,21

In one study, curcumin inhibited the growth of liver cancer cells, while also promoting their death by apoptosis. And in a mouse model of liver cancer, treatment with curcumin caused the tumors to grow much more slowly.22

And, in an exciting development, a study published in 2018 showed that when curcumin is combined with the AMPK-activator drug metformin, the combination worked better than either alone in preventing growth, metastasis, and new blood vessel formation in hepatocellular carcinoma, the most common—and most deadly—type of liver cancer.23

Lung Cancer

A new study shows that
curcumin sharply restricts
cancer cells’ ability to
extract energy from
glucose in the blood.

Lung cancer continues to be the top cause of cancer-related deaths, making it a huge priority for prevention.24,25

An abundance of animal and basic lab studies show curcumin’s potential against lung cancer.

For example, curcumin has been shown to reduce the growth of implanted human lung cancers in mice.26  Lab studies on lung cancer show that curcumin alters proteins required for metastasis, boosting the function of immune cells that are inactivated by cancers, and targeting blood vessel growth.24,26,27

A unique way in which curcumin combats lung cancer is by modulating microRNA inside cancer cells.28-30 These short stretches of genetic material regulate how the main genes in tumor cells are translated into functional proteins.

Studies reveal that curcumin inhibits lung cancer cell growth by downregulating a gene that promotes tumor formation, while upregulating genes that suppress transformation.28 Other research shows similar favorable modulation of miRNAs involved in metastatic spread.30

Summary

Curcumin is the polyphenol that gives the yellow color to the spice turmeric. It has been front and center in the scientific press for years—mostly recognized for its ability to suppress inflammation.2,31,32

Curcumin has also been shown to prevent cancer progression through a variety of mechanisms. Most recently, a study found that curcumin starves cancer cells of much-needed energy.

This mechanism is especially appealing for cancer prevention because it would target the great majority of cancers.

This confirms previous studies showing that curcumin has specific effects against colorectal, breast, prostate, lung, and liver cancers.

Starving malignant cells of their energy supply is an ideal way of boosting our bodies’ natural cancer resistance, helping it quench cancer long before a tumor is detectable.

If you have any questions on the scientific content of this article, please call a Life Extension® Wellness Specialist at 1-866-864-3027.

References

1. Available at: https://www.ncbi.nlm.nih.gov/pubmed/?term=curcumin+and+cancer. Accessed September 21, 2018.
2. Bianchi G, Ravera S, Traverso C, et al. Curcumin induces a fatal energetic impairment in tumor cells in vitro and in vivo by inhibiting ATP-synthase activity. Carcinogenesis. 2018 Sep 21;39(9):1141-50.
3. Carroll RE, Benya RV, Turgeon DK, et al. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer Prev Res (Phila). 2011 Mar;4(3):354-64.
4. He ZY, Shi CB, Wen H, et al. Upregulation of p53 expression in patients with colorectal cancer by administration of curcumin. Cancer Invest. 2011 Mar;29(3):208-13.
5. James MI, Iwuji C, Irving G, et al. Curcumin inhibits cancer stem cell phenotypes in ex vivo models of colorectal liver metastases, and is clinically safe and tolerable in combination with FOLFOX chemotherapy. Cancer Lett. 2015 Aug 10;364(2):135-41.
6. Bimonte S, Barbieri A, Palma G, et al. Dissecting the role of curcumin in tumour growth and angiogenesis in mouse model of human breast cancer. Biomed Res Int. 2015;2015:878134.
7. Wang Y, Yu J, Cui R, et al. Curcumin in Treating Breast Cancer: A Review. J Lab Autom. 2016 Dec;21(6):723-31.
8. Ferreira LC, Arbab AS, Jardim-Perassi BV, et al. Effect of Curcumin on Pro-angiogenic Factors in the Xenograft Model of Breast Cancer. Anticancer Agents Med Chem. 2015;15(10):1285-96.
9. Kumar U, Sharma U, Rathi G. Reversal of hypermethylation and reactivation of glutathione S-transferase pi 1 gene by curcumin in breast cancer cell line. Tumour Biol. 2017 Feb;39(2):1010428317692258.
10. Available at: https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html. Accessed September 24, 2018.
11. Sundram V, Chauhan SC, Ebeling M, et al. Curcumin attenuates beta-catenin signaling in prostate cancer cells through activation of protein kinase D1. PLoS One. 2012;7(4):e35368.
12. Liu T, Chi H, Chen J, et al. Curcumin suppresses proliferation and in vitro invasion of human prostate cancer stem cells by ceRNA effect of miR-145 and lncRNA-ROR. Gene. 2017 Oct 5;631:29-38.
13. Yang J, Wang C, Zhang Z, et al. Curcumin inhibits the survival and metastasis of prostate cancer cells via the Notch-1 signaling pathway. APMIS. 2017 Feb;125(2):134-40.
14. Hong JH, Lee G, Choi HY. Effect of curcumin on the interaction between androgen receptor and Wnt/beta-catenin in LNCaP xenografts. Korean J Urol. 2015 Sep;56(9):656-65.
15. Ide H, Lu Y, Noguchi T, et al. Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer. Cancer Sci. 2018 Apr;109(4):1230-8.
16. Armandari I, Hamid AR, Verhaegh G, et al. Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy. Prostate Int. 2014 Sep;2(3):105-13.
17. Global Burden of Disease Liver Cancer C, Akinyemiju T, Abera S, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015. JAMA Oncol. 2017 Dec 1;3(12):1683-91.
18. Dai XZ, Yin HT, Sun LF, et al. Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev. 2013;14(6):3855-9.
19. Marquardt JU, Gomez-Quiroz L, Arreguin Camacho LO, et al. Curcumin effectively inhibits oncogenic NF-kappaB signaling and restrains stemness features in liver cancer. J Hepatol. 2015 Sep;63(3):661-9.
20. Elmansi AM, El-Karef AA, Shishtawy M, et al. Hepatoprotective Effect of Curcumin on Hepatocellular Carcinoma Through Autophagic and Apoptic Pathways. Ann Hepatol. 2017 Jul-Aug;16(4):607-18.
21. Tsai CF, Hsieh TH, Lee JN, et al. Curcumin Suppresses Phthalate-Induced Metastasis and the Proportion of Cancer Stem Cell (CSC)-like Cells via the Inhibition of AhR/ERK/SK1 Signaling in Hepatocellular Carcinoma. J Agric Food Chem. 2015 Dec 9;63(48):10388-98.
22. Pan Z, Zhuang J, Ji C, et al. Curcumin inhibits hepatocellular carcinoma growth by targeting VEGF expression. Oncol Lett. 2018 Apr;15(4):4821-6.
23. Zhang HH, Zhang Y, Cheng YN, et al. Metformin incombination with curcumin inhibits the growth, metastasis, and angiogenesis of hepatocellular carcinoma in vitro and in vivo. Mol Carcinog. 2018 Jan;57(1):44-56.
24. Liu D, You M, Xu Y, et al. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer. Int Immunopharmacol. 2016 Oct;39:265-72.
25. Available at: https://www.cancer.org/latest-news/facts-and-figures-2018-rate-of-deaths-from-cancer-continues-decline.html. Accessed September 24, 2018.
26. Chen QY, Jiao DM, Yao QH, et al. Expression analysis of Cdc42 in lung cancer and modulation of its expression by curcumin in lung cancer cell lines. Int J Oncol. 2012 May;40(5):1561-8.
27. Xu X, Zhu Y. Curcumin inhibits human non-small cell lung cancer xenografts by targeting STAT3 pathway. Am J Transl Res. 2017;9(8):3633-41.
28. Lelli D, Pedone C, Majeed M, et al. Curcumin and Lung Cancer: the Role of microRNAs. Curr Pharm Des. 2017;23(23):3440-4.
29. Liu WL, Chang JM, Chong IW, et al. Curcumin Inhibits LIN-28A through the Activation of miRNA-98 in the Lung Cancer Cell Line A549. Molecules. 2017 Jun 3;22(6).
30. Zhan JW, Jiao DM, Wang Y, et al. Integrated microRNA and gene expression profiling reveals the crucial miRNAs in curcumin anti-lung cancer cell invasion. Thorac Cancer. 2017 Sep;8(5):461-70.
31. Chadalapaka G, Jutooru I, Chintharlapalli S, et al. Curcumin decreases specificity protein expression in bladder cancer cells. Cancer Res. 2008 Jul 1;68(13):5345-54.
32. Kelany ME, Hakami TM, Omar AH. Curcumin improves the metabolic syndrome in high-fructose-diet-fed rats: role of TNF-alpha, NF-kappaB, and oxidative stress. Can J Physiol Pharmacol. 2017 Feb;95(2):140-50.

HEALTH PROTOCOLS - STROKE by Life Extension

A stroke is the result of loss of blood flow, and subsequent oxygen, to part of the brain. Decreased blood flow to parts of the brain can be caused by blockage ...

HEALTH PROTOCOLS

Stroke

Overview

What is a Stroke?

A stroke is the result of loss of blood flow, and subsequent oxygen, to part of the brain. Decreased blood flow to parts of the brain can be caused by blockage, often from blood clots (ischemic stroke), or by the rupture of a brain blood vessel and subsequent hemorrhaging (hemorrhagic stroke). Strokes are one of the top causes of death and disability.

Ischemic and hemorrhagic strokes are severe and life-threatening. Other less severe types of strokes include transient ischemic attacks (“mini strokes” that resolve within 24 hours) and “silent” strokes that do not cause overt stroke-like symptoms.

Natural interventions such as olive leaf extract and olive oil as well as certain B-vitamins can help reduce the risk of a stroke.

Note: Emergency treatment within 4.5 hours of the onset of a stroke is essential. If you or someone you know exhibit any signs of a stroke, immediately call 911.

What are the Risk Factors for Stroke?

• Age
• Genetic factors
• High blood pressure
• High LDL cholesterol
• Insulin resistance/glucose intolerance
• Sleep apnea
• History of stroke or transient ischemic attack, and others

What are the Signs and Symptoms of a Stroke?

• Sudden numbness or weakness in face or limbs, usually on one side of the body
• Sudden confusion or difficulty speaking or understanding
• Sudden loss of vision
• Sudden severe headache with no apparent cause
• Sudden difficulty walking, dizziness, or loss of balance

Note: If you or someone you know experience stroke-like symptoms call 911 immediately, even if you are unsure whether a stroke occurred.

What are the Conventional Medical Treatments for Stroke?

• Emergency treatments for ischemic stroke:
• Intravenous tissue plasminogen activator (tPA) (ie, an enzyme that leads to clot breakdown)
• Aspirin and antiplatelet agents
• Surgery
• Secondary ischemic stroke prevention may include antiplatelet therapy such as low-dose aspirin or anticoagulant therapy such as warfarin. For patients who cannot take blood thinners, a surgical procedure called left atrial appendage occlusion is another option.
• Emergency treatments for hemorrhagic stroke:
• Surgery to stop the bleeding and drain the blood outside blood vessels
• Vitamin K if the patient was taking warfarin, to counteract its effects
• Nimodipine to control vasospasm and lower blood pressure
• Secondary hemorrhagic stroke prevention may include medications to control blood pressure.

What Natural Interventions Can Help Prevent a Stroke?

Note: Adhering to a Mediterranean-style diet has been associated with reduced all-cause mortality and lower incidence of several age-related diseases, including stroke.

• Olive leaf and olive oil. Olive, an important constituent of the Mediterranean diet, has anti-hypertensive and anti-atherosclerotic effects. A study showed older subjects who consumed olive oil had a 41% lower risk of ischemic stroke than subjects who never consumed olive oil.
• Nattokinase. Nattokinase, an enzyme extracted from fermented soybeans, can help reduce blood pressure in hypertensive patients. Nattokinase reduces the viscosity of blood, lowering blood pressure and clot risk.
• L-carnitine. L-carnitine, a cofactor in the metabolism of lipids, has been shown in preclinical studies to be neuroprotective.
• Vinpocetine. Vinpocetine is a derivative of vincamine, an extract from periwinkle. It has neuroprotective and cerebral blood flow-enhancing properties, as well as anti-inflammatory action.
• Vitamin D. Vitamin D deficiency is an independent risk factor for stroke in certain populations. A study also showed subjects with higher vitamin D levels had the lowest incidence of heart attack and stroke.
• Vitamins B6, B12, and folic acid. Treatment with these B-vitamins can lower stroke risk and overall stroke incidence. A review found that B-vitamin supplementation reduces stroke risk by approximately 12%.
• Omega-3 fatty acids. Omega-3 fatty acids have cerebrovascular protective abilities. In addition to clinical studies demonstrating cardioprotective abilities, a preclinical study found treatment with the omega-3 fatty acid docosahexaenoic acid (DHA) decreased mouse brain damage after an ischemic stroke.
• Dehydroepiandrosterone (DHEA). DHEA improves arterial dilation and protects against endothelial dysfunction. Higher levels of a DHEA metabolite have been associated with less severe strokes.
• Other natural interventions that may reduce the risk of stroke include garlic, vitamin C, flavonoids (eg, resveratrol), and rutin.

Introduction

Stroke is a major killer of Americans, claiming a life every 4 minutes, and is a leading cause of disability (Roger 2012; NSA 2012e). According to a 2012 report from the American Heart Association, about half of stroke survivors 65 or older had some difficulty with movement on one side of their body and over a quarter were institutionalized or in a nursing home 6 months following their stroke (Roger 2012).

A stroke is the result of loss of blood flow, and subsequently oxygen, to part of the brain. Stroke can be caused by either blockage, or rupture and subsequent hemorrhage (bleeding), of a blood vessel in the brain (PubMed Health 2012).

About 54% of stroke deaths happen outside of the hospital. This is partly because many stroke victims do not get to the hospital in time to receive potentially life-saving treatment (Washington State Dept. of Health 2012; Roger 2012).

Receiving emergency treatment within 4.5 hours of stroke onset can mean the difference between life and death (Del Zoppo 2009; Miller 2012). Unfortunately, one study showed that the median time to emergency department admission was 16 hours after onset of stroke symptoms. Only about half of the patients in this study were able to identify one stroke symptom (Zerwic 2007). Knowledge of signs and symptoms of stroke can help victims and their caregivers obtain emergency treatment in a timely manner (NSA 2012e; Roger 2012).

In addition to knowing how to react if stroke symptoms occur, Life Extension emphasizes the need for all aging individuals to take proactive stroke prevention measures. Also, recognition of an epidemic of “silent” strokes is critical. Silent strokes, or mini-strokes, do not cause outright stroke symptoms, but are associated with cognitive dysfunction and increase risk for overt stroke. Estimates indicate that over a quarter of the elderly population has experienced a silent stroke (Saini 2012; Masuda 2001; Lim 2010). Being aware of and taking steps to modify factors that increase stroke risk is paramount in reducing the likelihood of having a stroke or silent stroke (Slark 2012; Lim 2010). In one study, over 40% of possible stroke patients were unable to identify one stroke risk factor (Kothari 1997).

Maintaining optimal blood pressure levels is one of the most important ways to minimize stroke risk. For example, research suggests that people with blood pressure lower than 120/80 mmHg are about half as likely to suffer a stroke as those with higher blood pressure. It has also been reported that each 20/10 mmHg increase over 115/75 mmHg doubles the risk of several vascular complications, including heart attack, heart failure, stroke, and kidney disease (Franco 2004). Similarly, having impaired glucose tolerance nearly doubles stroke risk. Low levels of HDL-cholesterol (“good cholesterol”) and heart rhythm irregularities also significantly increase chances of having a stroke, and people with sleep apnea have twice the risk (Roger 2012).

The good news is that dietary and lifestyle management strategies coupled with natural compounds and certain drugs can target stroke risk factors. Also, comprehensive blood testing can help identify correctable factors involved in stroke and thus help guide prevention strategies.

This protocol will review the different types of stroke and their causes, risk factors, signs, and symptoms. Conventional treatments will be discussed, and strategies to mitigate stroke risk using integrative and scientifically studied natural modalities will be examined. ​

Types of Stroke

There are two main kinds of stroke, ischemic stroke, which makes up about 87% of all strokes, and hemorrhagic stroke (Roger 2012). Transient ischemic attacks (TIAs) and silent strokes are less severe types of stroke, but both can have long-term consequences such as memory impairment (Blum 2012; Wang 2013; NICE 2008; NSA 2009; Das 2008).

Ischemic stroke. An ischemic stroke arises from blockage of blood supply to part of the brain. There are 2 kinds of ischemic stroke: thrombotic and embolic.

• Thrombotic stroke. A thrombotic stroke is caused by a blood clot forming in a blood vessel leading to or in the brain and disrupting blood flow to part of the brain (NSA 2012b).
• Embolic stroke. Embolic stroke occurs when a blood vessel supplying the brain is blocked by circulating debris (ie, an embolus) that originated elsewhere in the body, such as when clots form on artificial heart valves or in the upper chamber of the heart. Embolic strokes are typically caused by blood clots (NSA 2012b).

Hemorrhagic stroke. Strokes caused by blood vessel(s) breaking and leaking blood into the brain are called hemorrhagic strokes. Hemorrhagic strokes account for about 13% of all strokes, but are responsible for more than 30% of all stroke deaths. There are 2 types of hemorrhagic stroke: subarachnoid and intracerebral (NSA 2012b, Roger 2012).

• Intracerebral hemorrhage. Intracerebral hemorrhage is the most common form of hemorrhagic stroke. It occurs when a blood vessel within the brain ruptures and leaks blood into the surrounding tissue. High blood pressure is the primary cause of this type of hemorrhage. Most intracerebral hemorrhages are accompanied by a sudden onset of symptoms, such as loss of consciousness, nausea or vomiting, numbness of the face, or severe headache with no known cause (NSA 2009a).
• Subarachnoid hemorrhage. Subarachnoid hemorrhage is usually caused by an aneurysm, a bulge in a blood vessel wall, bursting in a large artery on or near the delicate membrane surrounding the brain. Blood spills into the area around the brain, which is filled with protective cerebrospinal fluid (CSF). This causes the brain to be surrounded by blood-contaminated CSF. While there are no warning signs for a subarachnoid hemorrhage, symptoms could include a sudden severe headache often described by patients as the "worst headache of my life." At least 30% of subarachnoid hemorrhages lead to a condition called vasospasm, which occurs when blood vessels irritated by excess blood begin to spasm and narrow in size. This makes it difficult to supply the brain with enough blood to survive.

Transient ischemic attack. A transient ischemic attack (TIA), or “mini stroke”, can cause symptoms similar to a stroke, but they usually last only a few hours and are resolved within 24 hours. An example of a symptom shared by both stroke and TIA is visual abnormalities such as sudden vision loss. Since TIAs are short (ie, transient), they do not result in significant permanent brain damage (NICE 2008; NSA 2012d). However, history of TIA increases future stroke risk (Lager 2012,Easton 2009).

Silent stroke. Silent strokes lack overt stroke-like symptoms and commonly go unnoticed (Vermeer 2007). However, silent strokes typically cause lesions in the brain, which can be detected using imaging such as magnetic resonance imaging (MRI). These lesions, known as brain infarcts, are associated with age-dependent memory loss and reduced brain volume (Blum 2012). Studies suggest that silent stroke is a hidden epidemic among American’s, with up to 40% of people over age 70 exhibiting signs (Lim 2010). It is estimated that silent strokes are 5 times more common than symptomatic strokes (Wang 2013).

A silent stroke differs from a transient ischemic attack (TIA) in that TIA symptoms are detectable but usually only last a short time (NICE 2008). Silent strokes can be the result of minor hemorrhages, or they could be lacunar infarcts, in which a penetrating artery becomes occluded, resulting in lesions in the brain's white matter (Yatsu 2004; Norrving 2003). In a study of 2040 stroke-free subjects with an average age of 62, over 10% showed signs of silent stroke when examined by MRI, even though they were not aware of any symptoms (Das 2008).

Warning Signs of Stroke (NSA 2012a): Sudden numbness or weakness of face or limbs, usually on one side of the body Sudden confusion or trouble speaking or understanding Sudden loss of vision Sudden severe headache with no apparent cause Sudden trouble walking, dizziness, or loss of balance and coordination If you experience stroke-like symptoms call 911 without delay, even if it is unclear whether a stroke has occurred.

​

Complications of Stroke

Cognitive abilities, perception, coordination, speech, and balance can be impaired by a stroke. Paralysis is also possible. The specific effects depend on the location and extent of brain damage. For example, since the right hemisphere of the brain controls movement of the left side of the body, a stroke in the right hemisphere can cause paralysis on the left side of the body. A stroke in the cerebellum can cause problems with balance and coordination, and a brainstem stroke can damage involuntary "life-support" functions such as breathing and heart rate and could lead to death. The five most common complications of stroke that render many patients disabled are aphasia, pain, pseudobulbar affect, vascular dementia, and paralysis/spasticity (NSA 2012c,g,f).

• Aphasia. About 25% of all stroke survivors experience aphasia - impairment of the ability to speak and understand spoken or written language. Aphasia is the result of stroke-induced damage to brain regions involved in speech and language processing. Many patients with aphasia benefit from speech/language therapy (NSA 2012g; Mayo Clinic 2012c).
• Pain. Stroke victims may experience pain immediately following a stroke or weeks to months later. Some stroke victims experience local or mechanical pain that may be isolated to joints. This type of pain is caused by damaged muscle or other soft tissue. Other victims may experience a chronic central pain caused by damage to the brain. Central pain occurs because the damaged brain does not interpret pain messages properly, and may register even the slightest touch as painful (NSA 2012f).
• Pseudobulbar affect. A stroke that damages areas in the brainstem and cerebral cortex can cause a condition called pseudobulbar affect, which results in uncontrollable episodes of laughing or crying - often disrupting normal social interaction. Up to 52% of stroke victims report at least some symptoms of pseudobulbar affect (Rosen 2008; Parvizi 2001).
• Vascular Dementia. It is estimated that almost one-fifth of stroke victims will develop problems with their mental and cognitive abilities (NSA 2012c). This loss of intellectual ability is called vascular dementia and results from tissue damage caused by reduced blood flow to the brain. Evidence suggests that stroke doubles the risk of dementia (Sahathevan 2012). Common symptoms of vascular dementia include memory loss, confusion, and decreased attention span (Pendlebury 2009).
• Paralysis & Spasticity. Some stroke victims experience complete paralysis - the inability to voluntarily move muscles. In other cases, patients may experience a tightening or stiffness of muscles that impairs movement of the arms and/or legs. This condition, called spasticity, occurs because messages from parts of the brain to muscles are not properly conveyed (NSA 2010). In some cases, the damaged brain sends signals to muscles to contract for long periods of time, causing painful muscle spasms similar to severe cramping (Bhakta 2000).

Risk Factors for Stroke

Age, gender, race, ethnicity, and genetics have all been identified as non-modifiable risk factors for stroke, with age being the most important (Sacco 1997; Khaw 2006; Francis 2007).

• Age. The stroke rate more than doubles in men and women for each 10 years over age 65.
• Gender. Stroke rates are higher in men than women, but more women die of stroke each year.
• Race & ethnicity. Stroke rates vary extensively among different racial groups. For example, African-Americans are statistically twice as likely to die from strokes as whites. Stroke incidence has risen sharply in Chinese and Japanese populations. Specifically, stroke leads heart disease as a cause of death in Japan.
• Genetics/ hereditary factors. The Framingham Offspring Study demonstrated that family history of stroke is a strong predictor of future stroke risk.

Modifiable stroke risk factors include:

High Blood Pressure

Hypertension, the strongest risk factor for cardiovascular disease worldwide, is associated with about half of ischemic strokes (Kokubo 2012). Also, estimates indicate that 17 to 28% of hemorrhagic strokes among people with high blood pressure could be prevented with blood-pressure lowering treatment (Woo 2004). About 1 in 3 American adults have high blood pressure (AHA 2012b). According to the Cardiovascular Lifetime Risk Pooling Project, men with hypertension throughout middle age have the highest lifetime risk for stroke (Allen 2012).

Blood pressure is measured as systolic and diastolic pressure. Systolic pressure is measured when blood is expelled from the heart as it contracts. Diastolic pressure is measured between contractions. Systolic is the “top” or “first” number, diastolic is the “bottom” or “second”. For most aging individuals, Life Extension recommends an optimal blood pressure target of 115/75 mmHg.

Many clinicians have not adequately addressed the problem of hypertension because of the lax conventional definition of "acceptable" blood pressure. In 2012, it was shown that men and women with consistent blood pressure below 120/80 mmHg had the lowest lifetime risk of stroke and cerebrovascular disease (Allen 2012). It has also been reported that each 20/10 mmHg increase over 115/75 mmHg doubles the risk of several vascular complications, including heart attack, heart failure, stroke, and kidney disease (Franco 2004). Unfortunately, studies have shown that some medical professionals are unlikely to aggressively treat hypertension until blood pressure levels reach 160/90 mmHg (Hyman 2002).

Elevated blood pressure can contribute significantly to endothelial dysfunction> - impairment of normal function of the endothelium, the delicate cellular lining of the inside of blood vessels (Del Turco 2012; Davel 2011). High blood pressure can alter the endothelium and decrease the motility of the arteries and stiffen the arterial wall (Felmeden 2003). When arteries become stiff, they no longer contract and dilate normally, placing stress on the heart (NIH 2011). High blood pressure also contributes to atherosclerosis and blood clot formation. Refer to the Blood Pressure Management Protocol for more information.

Elevated Homocysteine Homocysteine is an amino acid derivative that can damage blood vessels. High homocysteine levels have been associated with an increased risk of stroke recurrence (1.74-fold) and all-cause death (1.75-fold) (Zhang 2010). Homocysteine disrupts endothelial tissue and inhibits the growth of new endothelial cells, which contributes to atherosclerotic plaque formation. Homocysteine can also disrupt the function of brain cells and compromise their survival (Manolescu 2010).

Life Extension recommends an optimal homocysteine level of less than 8 µmol/L. One comprehensive review showed that every 2.5 µmol/L increase above this level is associated with about a 20% increase in stroke risk (Homocysteine Studies Collaboration 2002).

C - reactive protein (hsCRP) C-reactive protein (CRP) is a protein in the blood that correlates with the level of systemic inflammation (Huang 2012b). Elevated CRP measured by a high-sensitivity C-reactive protein blood test is associated with incidence and severity of stroke. C-reactive protein is synthesized by liver cells, and its rate of synthesis is regulated by pro-inflammatory proteins such as interleukin-6 and interleukin-1. While in healthy humans the level of hsCRP is relatively low, it becomes elevated with inflammation, infection, and tissue damage (Casas 2008).

The Cardiovascular Health Study and Emerging Risk Factors Collaboration, both performed a decade ago, found that elevated hsCRP is a risk factor for stroke and can predict stroke outcome. In 2008, the JUPITER trial, which involved 17 802 healthy subjects with hsCRP levels greater than or equal to 2.0 mg/L, found that cholesterol-lowering statin drugs significantly reduced stroke incidence. This may be due in part to an anti-inflammatory effect of statins (Everett 2010; Elkind 2010). In a group of Chinese patients, high levels of C-reactive protein (above 3 mg/L) 15 days before ischemic stroke onset independently predicted death within 3 months (Huang 2012b). Another study involving 467 subjects found that elevated (highest vs. lowest quartile) hsCRP was associated with a more than 4-fold increase in risk of death over 4-years of follow-up after first ischemic stroke (Elkind 2010).

The plasma level of hsCRP is a powerful predictor of endothelial dysfunction, stroke, and vascular death in individuals without known cardiovascular disease. Levels of hsCRP higher than 1.5 mg/L are associated with an increased risk of death after ischemic stroke (Di Napoli 2001). Elevated levels of hsCRP may also be a predictor of secondary cerebrovascular events after an initial stroke (Di Napoli 2005). Life Extension recommends an optimal blood level for hsCRP of less than 0.55 mg/L in men and less than 1.0 mg/L in women.

Excess Fibrinogen

Fibrinogen is a component of blood involved in the clotting/coagulation process. It is converted through enzymatic reactions into the protein fibrin, which binds with other proteins to form a clot. High levels of fibrinogen are associated with cerebrovascular disease, even when other known risk factors such as cholesterol are normal (Kaslow 2011). A study in a Taiwanese population indicated that excess fibrinogen is a major independent predictor of future stroke risk (Chuang 2009). Life Extension recommends an optimal fibrinogen blood level of 295 - 369 mg/dL.

High LDL Cholesterol

Cholesterol, found in all the body's cells, is important for normal cellular function. Cholesterol is carried to and from cells by lipoproteins (high-density lipoprotein [HDL] and low-density lipoprotein [LDL]). LDL (“bad cholesterol”) can contribute to buildup of plaque in arterial walls (AHA 2012d). Studies indicate that high levels of LDL and triglycerides are associated with increased risk of stroke and transient ischemic attack. Statins, drugs that lower LDL cholesterol, reduce stroke risk by as much as 18% and reduce stroke-related deaths by 13% (Rothwell 2011). High levels of HDL (“good cholesterol”) are associated with reduced risk of stroke or cerebrovascular disease (Sacco 2001).

Cholesterol-lowering statin drugs not only reduce the incidence of first stroke, but also reduce chances of having a second, often more debilitating stroke. Statin use is recommended in those who have already experienced a stroke or transient ischemic attack and have an LDL cholesterol level of 100 mg/dL or higher, with the aim of reaching an optimal level of 70 mg/dL (Davis 2012). Life Extension recommends optimal HDL levels over 50-60 mg/dL. Refer to the Cholesterol Management protocol for more information.

Insulin Resistance / Glucose Intolerance

Insulin resistance is a metabolic disorder characterized by reduced sensitivity to the hormone insulin, which regulates blood sugar levels. Insulin signals cells to uptake glucose from the blood. In conditions where insulin levels are low or insulin does not function properly, such as diabetes, blood sugar levels are abnormal. Insulin resistance occurs when insulin levels are normal but its ability to regulate blood sugar is impaired. This results in elevated blood sugar. The insulin-resistant state is associated with hypertension, endothelial dysfunction, abnormal fibrinogen levels, and increased concentrations of LDL particles in the bloodstream (Furie 2008).

In a multiethnic, population-based study of non-diabetic individuals, insulin resistance was associated with a 2.8-fold increased occurrence of a first ischemic stroke (Rundek 2010). This result corroborates previous observational findings that insulin resistance is an independent risk factor for stroke. In the Helsinki Policeman Study, which involved 970 healthy men aged 34 to 64, the rate of stroke incidence was 2-fold higher in diabetes-free patients with higher insulin concentrations (top tertile) compared to those with lower insulin concentrations over a 22-year follow-up (Furie 2008; Pyorala 2000). Refer to the Diabetes protocol for more information.

Sleep Apnea

Many aging individuals suffer from episodic breathing lapses during sleep. This is called sleep apnea. The most common form of sleep apnea occurs when the upper airway collapses (partially or completely) for intermittent periods. This results in characteristic gasping or choking during nighttime breathing (Das 2012).

Sleep apnea deprives its victims of oxygen during sleep. Lack of oxygen due to sleep apnea is associated with inflammation, endothelial dysfunction, and oxidative stress. All of these factors compromise the integrity of blood vessels, increasing the likelihood a stroke-causing blood clot will form. Sleep apnea is independently associated with significantly increased stroke risk, ranging from about 1.5-fold to over 4-fold across several studies, but also may aggravate stroke risk factors such as high blood pressure, atrial fibrillation, and diabetes (Das 2012). One study showed that people with sleep apnea are more likely to die within the first month following stroke than those who breathe normally during sleep (Mansukhani 2011).

Many people with sleep apnea may not know they have it. Participating in a clinical sleep study is the most accurate way to assess sleep quality. Identification and correction of sleep apnea can significantly reduce overall cardiovascular risk (Buchner 2007). ​

Stroke Diagnosis and Treatment

Ischemic stroke damage is time-dependent. Following initial arterial occlusion, cell death cascades to greater areas of the brain until blood flow is reestablished (van der Worp 2007). Hemorrhagic stroke damage is also time-dependent. As blood continues to leak from the original rupture site, the area of the brain damaged by the hematoma increases (Qureshi 2001). It is therefore critical to treat stroke victims as fast as possible to avoid widespread brain damage.

Once a stroke victim has arrived at the hospital, physicians use imaging tests to determine what kind of stroke (ischemic or hemorrhagic) occurred (PubMed Health 2011). Determining the type of stroke is critical because the medications used to treat ischemic stroke will not work for hemorrhagic stroke, and vice versa (Lansberg 2012).

Brain imaging can help detect strokes and determine their nature.

• Computerized tomography angiography (CTA). Computerized tomography angiography is utilized to look for aneurysms, arterial and venous malformations, as well as narrowing of arteries in the neck and brain.
• Computerized tomography (CT). Computerized tomography is a medical imaging tool that can be used to identify cerebral hemorrhaging.
• Magnetic resonance imaging (MRI). Magnetic resonance imaging techniques can aid in the diagnosis of stroke (Schellinger 1999).
• Magnetic resonance angiography (MRA). Magnetic resonance angiography uses a magnetic field, radio waves, and a dye injected into the veins to evaluate arteries in the neck and brain.

Emergency treatment of ischemic stroke. Treatment of ischemic stroke within 4.5 hours of symptom onset is critical. Studies show that rapid dissolution of the blood clot within 4.5 hours of symptom onset can dramatically reduce brain damage (Lansberg 2012). Unfortunately, many ischemic stroke patients do not get to the hospital and receive the appropriate thrombolytic agent until significant brain damage has already occurred (Zerwic 2007).

• Intravenous injection of tissue plasminogen activator (tPA). tPA is FDA-approved to treat acute ischemic stroke (Roth 2011). tPA is an enzyme that converts plasminogen to plasmin - the major enzyme that stimulates clot breakdown. It helps decrease ischemic injury and salvage brain tissue. tPA administration within 4.5 hours of symptom onset is a first choice therapy among patients with no contraindications (Miller 2012; Del Zoppo 2009).Unfortunately, studies indicate that only 2 - 8% of ischemic stroke patients receive this potentially life-saving treatment (Alberts 2012). One study found that 18% of these treatment omissions are avoidable (Cocho 2005). In fact, in many instances, even eligible patients may be denied tPA treatment (Alberts 2012). Sadly, bureaucratic barriers, such as legal liability concerns and insufficient insurance reimbursement, contribute to these deadly denials (Bambauer 2006).Another oft-cited reason for tPA avoidance during acute ischemic stroke treatment is bleeding risk. Physicians often hesitate to treat ischemic stroke victims with tPA if the patient has been taking warfarin for fear of brain hemorrhage. However, evidence suggests that warfarin-treated stroke victims whose INR is less than or equal to 1.7 can be treated with tPA without excess risk of intracranial hemorrhage (Xian 2012).Part of the burden of ensuring timely treatment lies with the patient and/or their caregivers as well. Doctors cannot deliver tPA within the critical 4.5 hour window if a stroke victim arrives at the hospital long after this period has expired. Unfortunately, one study showed that the median time to emergency department admission was 16 hours after onset of stroke symptoms (Zerwic 2007). Calling 911 immediately upon experiencing stroke symptoms is the patient’s and his/her caregivers’ role in ensuring optimal stroke treatment.
• Aspirin & antiplatelet agents. Aspirin is established as an important treatment for ischemic stroke. Studies have shown that 160 or 300 mg doses of aspirin given within 48 hours of ischemic stroke onset can reduce the death rate over time (at hospital discharge or at 6 months ) (van der Worp 2007).
• Surgical procedures. If necessary, emergency procedures must be performed as soon as possible. For example, if a burst aneurysm (a weakness in a blood vessel) causes associated subarachnoid hemorrhage in the brain, a surgeon can clip the aneurysm and stop the bleeding. Another procedure, called balloon angioplasty, can be used to improve blood flow in occluded arteries (Mayo Clinic 2012b).

Secondary ischemic stroke prevention. After stroke, there is a significant risk of a repeat stroke or secondary stroke (Geeganage 2012). To help prevent secondary stroke, patients may be prescribed anti-platelet therapy, including low-dose aspirin or Plavix®, or anticoagulant therapy such as long-term warfarin (Coumadin®) (Alberts 2011; Awada 2011; Bousser 2012).

Emergency treatment of hemorrhagic stroke. Emergency treatment of hemorrhagic stroke focuses on controlling bleeding and reducing pressure in the brain. Surgical procedures are often used to drain the blood that collects outside the blood vessels during a hemorrhage (hematoma) (Dey 2012). If older types of anticoagulant medication (eg, Coumadin®, also known as warfarin) had been taken to prevent blood clots, intervention with vitamin K may be used to counteract the effects of warfarin. Anti-clotting agents (eg, aspirin and tPA) may increase bleeding and cannot be used (Mayo Clinic 2012b).

The medication nimodipine, a calcium channel blocker, is often used to help control vasospasm and may improve outcome among patients with subarachnoid hemorrhage. Nimodipine lowers central blood pressure, and its ability to control vasospasm is thought to be due to inhibition of vasoconstriction (Choi 2012; NSA 2009a; BAF 2011; Kim 2009). An experimental drug called clazosentan, an endothelin receptor antagonist, has been reported in some human and animal studies to reduce the risk of blood vessel spasm and constriction after hemorrhagic stroke and greatly improve chances of survival (Schubert 2008; Sabri 2011; Macdonald 2012). However, other studies have failed to corroborate these findings, so more investigation is needed (Macdonald 2011).

Secondary hemorrhagic stroke prevention. After the acute treatment, medications may be prescribed to control blood pressure, which is a major risk factor for a second stroke (Rashid 2003). Prescription medications for lowering blood pressure include diuretics, calcium channel blockers, beta blockers, ACE inhibitors, and others (AHA 2012a).​

Approaches to Stroke Risk Reduction

Stroke risk reduction hinges upon targeting a variety of known risk factors such as high blood pressure, elevated cholesterol, and insulin resistance, as well as improving dietary and lifestyle habits. However, one of conventional medicine’s most powerful ischemic stroke risk-reduction strategies is to mitigate the likelihood of blood clots using anticoagulants and antiplatelet medications. It is critical to understand that these medications reduce ischemic stroke risk, but increase hemorrhagic stroke risk. Hemorrhagic stroke risk reduction strategies primarily focus on reducing blood pressure, rather than avoiding clotting (Brott 2000; van der Worp 2007; Davis 2012; Bronner 1995; Brisman 2006).

Anticoagulant medications.

Warfarin (Coumadin®), an anticoagulant, has been associated with a 64% reduction in ischemic stroke risk (Lip 2012). Warfarin reduces blood clotting by antagonizing the effects of vitamin K (Siguret 2008). However, warfarin can interact with other drugs, and people taking warfarin require constant monitoring to protect against excessive bleeding.

Recently approved oral anticoagulant drugs are now available to treat blood clots after orthopedic surgeries and may reduce stroke risk is some populations (Boehringer Ingelheim Pharmaceuticals 2012; Mannucci 2011; Ru San 2012). Dabigatran (Pradaxa®), which is a direct thrombin inhibitor, and rivaroxaban (Xarelto™), which inhibits an enzyme involved in coagulation called factor Xa, are examples of anticoagulants that have recently been approved for human use.

These newer therapies may have significant benefits over warfarin, which interferes with vitamin K metabolism. First, they both inhibit clotting factors that do not depend on vitamin K, so they are less sensitive to fluctuations of dietary vitamin K intake. Dabigatran does not exhibit major interactions with foods or other medications (Steffel 2011). Unlike warfarin, people taking these medications do not need regular blood testing to monitor coagulation (Thethi 2011). In clinical trials, both treatments were at least as effective as warfarin for reducing stroke risk in patients with atrial fibrillation, and preventing/treating deep vein thrombosis, with a reduced risk of bleeding (Connolly 2009; Schulman 2009; Eriksson 2008). For more information see the Blood Clot Prevention protocol.

Advantages of Pradaxa® vs. warfarin include:

• Rapid onset of action
• Predictable, consistent anticoagulant effects
• Low potential for drug-drug interaction
• No requirement for anticoagulant blood test monitoring
• Preliminary efficacy and safety advantages vs. warfarin based on initial head-to-head, hard-endpoint data
• No need to maintain low vitamin K levels. Insufficient vitamin K promotes arterial calcification.

Disadvantages of Pradaxa® vs. warfarin include:

• No antidote for reversal of over anti-coagulation effect. When too much warfarin is given and the patient's INR indicates they are at risk for a major bleed (or are pathologically bleeding), vitamin K can be injected to immediately reverse warfarin's anti-coagulant effect. If too much Pradaxa® is taken, there is no immediate antidote.
• No long-term safety data on Pradaxa® (the case with virtually all newly approved drugs)
• More expensive than warfarin

Anti-platelet medications. Platelets are cell fragments in the blood involved in clot formation. Anti-platelet drugs make these cell fragments less sticky and less likely to clot. The most frequently used anti-platelet medication is aspirin. Aggrenox®, combination of low-dose aspirin and the anti-platelet drug dipyridamole, may be prescribed instead (Norrving 2006). Other alternatives include clopidogrel (Plavix®) or ticlopidine (Ticlid®) (Merck Manual 2007; Forbes 1998; Aw 2012; Murray 1994).

Left atrial appendage occlusion. For some patients with atrial fibrillation and who cannot take anti-coagulants or other blood-thinners, a surgical procedure called left atrial appendage occlusion has been shown to inhibit clot formation and decrease stroke risk (Holmes 2009; Lopez-Minguez 2012). The left atrial appendage is a muscular pouch that serves as a reservoir for one of the chambers of the heart (left atrium). In the presence of arrhythmia, blood in the appendage is prone to clotting (Alli 2012). ​

Natural Strategies to Reduce Stroke Risk

Conventional medications and surgeries used to prevent stoke and cerebrovascular disease are often associated with side effects and are limited in their ability to target the multiple factors that contribute to stroke. Life Extension emphasizes a global stroke prevention strategy. This strategy includes a series of preventive measures such as reducing chronic inflammation, maintaining healthy body weight, reducing cholesterol, suppressing homocysteine and fibrinogen levels, and lowering blood pressure (Houston 2010).

Mediterranean Diet. The traditional Mediterranean diet is rich in fruits, vegetables, whole grains, and fish, and low in red meat and sweets (Fung 2009). Adherence to a Mediterranean diet is associated with reduced all-cause mortality and lower incidence of several age-related diseases, including stroke (Mitrou 2007; Fung 2009). A 2011 study found that strict adherence to a Mediterranean diet decreased the likelihood of ischemic stroke irrespective of cholesterol levels, age, and gender (Kastorini 2011). In a separate population study, adherence to a Mediterranean diet significantly decreased the risk of ischemic stroke, heart attack, and vascular death (Gardener 2011). In a study surveying over 70 000 American women, a "prudent" diet of fruits, vegetables, fish and whole grains was associated with a lower risk of total and ischemic stroke compared to a "Western" diet high in processed meats, refined grains, and sweets (Ding 2006). Consuming a Mediterranean diet low in red meat and rich in fresh fruits and vegetables can also curtail excess homocysteine levels in people genetically prone to high homocysteine (Dedoussis 2004).

Targeted Nutritional Interventions

Olive leaf & olive oil. The Olea Europaea plant is an important constituent of the diet of Mediterranean cultures, and has anti-hypertensive and anti-atherosclerotic effects (El 2009). The leaves of the olive tree contain the active compounds oleuropein and oleacein. In a human trial, 1000 mg daily of olive leaf extract reduced blood pressure (Perrinjaquet-Moccetti 2008). Pretreatment with 100 mg/kg of olive leaf extract has also been shown to reduce brain damage in a rat model of ischemic stroke (Dekanski 2011). Olive oil also contains heart-healthy compounds. A French study showed that older subjects who consume olive oil in both cooking and in dressing have a 41% lower ischemic stroke risk compared with people who never use olive oil (Samieri 2011).

Nattokinase. A 2008 study demonstrated that nattokinase, an enzyme extracted from fermented soybeans, is helpful in reducing blood pressure in patients with hypertension (Kim 2008). The participants that received 2000 fibrinolytic units (FU) of nattokinase daily for 8 weeks had a reduction in systolic and diastolic pressure of almost 6 mmHg and 3 mmHg, respectively. Nattokinase breaks apart the protein fibrinogen, which contributes to blood viscosity and clotting. This reduction in blood viscosity may be one of the ways that nattokinase affects blood pressure. Nattokinase also inhibits the elevation of angiotensin II in the bloodstream (Fujita 2011).

L-carnitine, acetyl-L-carnitine, and propionyl-L-carnitine. L-carnitine is an essential co-factor in the metabolism of lipid molecules into cellular energy. L-carnitine has been shown to be neuroprotective in rat models of ischemic stroke (Wainwright 2003). Laboratory studies on human tissue specimens demonstrate that L-carnitine causes vasodilation. In one laboratory study, L-carnitine selectively inhibited a platelet-activating factor, demonstrating that L-carnitine has a protective effect against thrombosis in ischemic stroke. In a sample of 9 ischemic muscle specimens from 5 patients with vascular disease, L-carnitine levels were low, but were restored 2 days after a single injection followed by a 30-minute infusion of propionyl-L-carnitine (Andreozzi 2009). In an animal model of ischemic stroke, pre-treatment with acetyl-L-carnitine decreased brain damage (Zhang 2012).

Vinpocetine. Vinpocetine is derived from the chemical vincamine, which is an extract from the leaves of the lesser periwinkle plant. Since its synthesis in the 1960s, vinpocetine has shown both neuroprotective and cerebral blood-flow-enhancing properties. It is widely used in cerebrovascular disease in Japan, Hungary, Poland, Russia, and Germany (Patyar 2011).

Vinpocetine has neuroprotective effects due to its ability to block sodium channels and calcium channels in brain cells, preventing excitotoxicity and death of brain tissue (Bereczki 2008). Animal models reveal a role for vinpocetine in blocking inflammatory processes. This is significant because chronic inflammation leads to endothelial dysfunction and atherosclerosis, increasing the risk for stroke. In an animal model of ischemic stroke, damage to a brain area known as the hippocampus was reduced from 77% in untreated animals to 37% in animals treated with vinpocetine (Patyar 2011). Note: Women who are pregnant or could become pregnant should not use vinpocetine.

Vitamin D. Evidence from clinical trials suggests that vitamin D plays a modest role in blood pressure control (Witham 2009). Vitamin D regulates blood pressure by modulating calcium-phosphate metabolism, controlling endocrine glands, and improving endothelial function. Vitamin D deficiency appears to be an independent risk factor for stroke incidence in Japanese-American men (Kojima 2012) and Korean men (Park 2012). A recent study also showed that individuals whose vitamin D levels were greater than 30 ng/mL had the lowest incidence of heart attack and stroke (Park 2012). Vitamin D may also promote normal insulin metabolism (Houston 2010).

Vitamin B6, B12, and Folic Acid. B-vitamin therapy has been shown to lower homocysteine levels and independently reduce stroke risk (Saposnik 2009). Homocysteine levels can become elevated when serum B12 level are below 400 pmol/L (Spence 2011). Analysis of data on 5522 participants in a large trial to assess the role of B-vitamins in stroke risk reduction (the HOPE-2 trial) demonstrated that treatment with folic acid and vitamins B6 and B12 lowered plasma homocysteine levels and overall stroke incidence. In this study, the incidence of both ischemic and hemorrhagic stroke was lower in the vitamin group compared to the placebo group (Saposnik 2009). A 2012 review of 19 different studies found that B-vitamin supplementation reduces stroke risk by approximately 12% (Huang 2012a). Another 2012 study supported those findings by demonstrating that supplementation with folic acid can reduce stroke incidence by 8% (Huo 2012).

Omega-3 fatty acids. Omega-3 fatty acids are found in certain fat sources such as cold-water fish and flaxseed oil (Houston 2010). Studies have demonstrated that omega-3 fatty acids help regulate blood pressure and reduce platelet aggregation, inflammation, LDL-cholesterol, and other atherosclerosis risk factors (AHA 2010). A 2006 review article indicated that omega-3 fatty acids have a significant protective effect against cerebrovascular disease (Wang 2006). In a mouse model of ischemia, 3 months of treatment with docosahexaenoic acid (DHA) blunted inflammatory responses after an ischemic stroke and decreased brain damage (Lalancette-Hebert 2011).

Omega-3 intake may slow the progression of atherosclerosis by reducing plasma triglyceride levels (Mozaffarian 2011). In short-term clinical trials, consumption of omega-3 fatty acids stimulated nitric oxide production, which enhances the dilation of arteries and improves blood flow throughout the body. Omega-3 fatty acids have also been shown to improve endothelial function and prevent abnormal heart rhythms (arrhythmias) (Mozaffarian 2011; Reiffel 2006; Singer 2004). The American Heart Association suggests that some people may not get enough omega-3 fatty acids through diet alone and that these individuals should consider taking a dietary supplement (AHA 2010).

Garlic. Some clinical trials have found that increased consumption of garlic can lower blood pressure in hypertensive patients. Consumption of approximately 10 000 mcg of the active ingredient allicin, the amount contained in about four cloves of garlic, per day appears to be necessary to lower blood pressure (Houston 2010). A review of studies demonstrated that garlic consumption appears to lower systolic and diastolic blood pressure by an average of 16 and 9 mmHg, respectively (Reinhart 2008).

Dehydroepiandrosterone (DHEA). DHEA, an endogenous steroid hormone derived from cholesterol, is the most abundant circulating steroid in humans. DHEA improves arterial dilation and protects against endothelial dysfunction, a risk factor for stroke (Kawano 2003). In a study of over 300 postmenopausal women, higher levels of DHEA-s, a major metabolic derivative of DHEA, were associated with less severe stroke (Pappa 2012).

Vitamin C. Vitamin C, also known as ascorbic acid, is a water-soluble antioxidant that improves endothelial function. Numerous observational and clinical studies have documented that dietary intake of vitamin C can lower blood pressure and heart rate. Evaluation of published clinical trials has shown that intake of 250 mg vitamin C twice daily lowered systolic and diastolic blood pressure by about 7 mmHg and 4 mmHg, respectively. Vitamin C may lower blood pressure by reducing binding of angiotensin II to its receptor. Vitamin C also appears to enhance antihypertensive effects of some blood pressure medications (Houston 2010).

Flavonoids. Flavonoids are naturally occurring antioxidants found in fruits, vegetables, red wine, and tea (Houston 2010). A 2012 study showed that increased intake of flavonoids is associated with reduced risk of ischemic stroke in women, and that consumption of citrus fruits can reduce overall stroke risk (Cassidy 2012). An animal model showed that a single intravenous dose of the flavonoid resveratrol improved cerebral blood flow by 30% and protected against ischemia-induced brain damage (Lu 2006).

Rutin. Rutin is a flavonoid that occurs naturally in buckwheat and some fruits (eg, apples) (Kreft 2006; Lata 2009). Rutin inhibits an enzyme called protein disulfide isomerase (PDI), which participates in blood clot formation. Among nearly 5000 agents screened as potential PDI inhibitors in one study, rutin was one of the most potent (Jasuja 2012). An animal model showed that rutin inhibits the formation of blood clots (Jasuja 2012). ​

---

Disclaimer and Safety Information

This information (and any accompanying material) is not intended to replace the attention or advice of a physician or other qualified health care professional. Anyone who wishes to embark on any dietary, drug, exercise, or other lifestyle change intended to prevent or treat a specific disease or condition should first consult with and seek clearance from a physician or other qualified health care professional. Pregnant women in particular should seek the advice of a physician before using any protocol listed on this website. The protocols described on this website are for adults only, unless otherwise specified. Product labels may contain important safety information and the most recent product information provided by the product manufacturers should be carefully reviewed prior to use to verify the dose, administration, and contraindications. National, state, and local laws may vary regarding the use and application of many of the treatments discussed. The reader assumes the risk of any injuries. The authors and publishers, their affiliates and assigns are not liable for any injury and/or damage to persons arising from this protocol and expressly disclaim responsibility for any adverse effects resulting from the use of the information contained herein.

The protocols raise many issues that are subject to change as new data emerge. None of our suggested protocol regimens can guarantee health benefits. The publisher has not performed independent verification of the data contained herein, and expressly disclaim responsibility for any error in literature.

References

Alberts MJ. Antithrombotic therapy for secondary stroke prevention. Continuum (Minneapolis, Minn.). Dec 2011;17(6 2ndary Stroke Prevention):1255-1266.

Alberts MJ. Cerebral hemorrhage, warfarin, and intravenous tPA: the real risk is not treating. JAMA: the journal of the American Medical Association. Jun 27 2012;307(24):2637-2639.

Allen N, Berry JD, Ning H, et al. "Impact of blood pressure and blood pressure change during middle age on the remaining lifetime risk for cardiovascular disease: the cardiovascular lifetime risk pooling project." Circulation 125(2012): 37-44

Alli O, Holmes DR, Jr. Left atrial appendage occlusion for stroke prevention. Current problems in cardiology. Oct 2012;37(10):405-441.

American Heart Association (AHA). “Fish and Omega-3 Fatty Acids.” Available at: http://www.heart.org/HEARTORG/General/Fish-and-Omega-3-Fatty-Acids_UCM_303248_Article.jsp. Last updated September 7, 2010. Accessed July 27, 2012.

American Heart Association (AHA). “Types of Blood Pressure Medications.” Available at: http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/PreventionTreatmentofHighBloodPressure/Types-of-Blood-Pressure-Medications_UCM_303247_Article.jsp. Last updated June 7, 2012a. Accessed July 27, 2012.

American Heart Association (AHA). “Understanding Blood Pressure Readings.” Available at: http://www.heart.org/HEARTORG/Conditions/HighBloodPressure/AboutHighBloodPressure/Understanding-Blood-Pressure-Readings_UCM_301764_Article.jsp. Last updated June 6, 2012b. Accessed July 27, 2012.

American Heart Association (AHA). Good vs. Bad Cholesterol. Available at: http://www.heart.org/HEARTORG/Conditions/Cholesterol/AboutCholesterol/Good-vs-Bad-Cholesterol_UCM_305561_Article.jsp. Last updated Sep 5, 2012d. Accessed Sep 19, 2012.

Andreozzi GM. "Propionyl l-carnitine: intermittent claudication and peripheral arterial disease." Expert.Opin.Pharmacother. 10(2009): 2697-2707

Aw D, Sharma JC. Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice? Postgraduate medical journal. Jan 2012;88(1035):34-37.

Awada A. [Primary and secondary prevention of ischemic stroke]. Le Journal medical libanais. The Lebanese medical journal. Oct-Dec 2011;59(4):213-219.

Bambauer KZ, Johnston SC, Bambauer DE, Zivin JA. Reasons why few patients with acute stroke receive tissue plasminogen activator. Archives of neurology. May 2006;63(5):661-664.

Bereczki D and Fekete I. "Vinpocetine for Acute Ischemic Stroke." Stroke (2008)

Bhakta BB. "Management of spasticity in stroke." Br.Med Bull. 56(2000): 476-485

Blum S, Luchsinger JA, Manly JJ, et al. "Memory after silent stroke: hippocampus and infarcts both matter." Neurology 78(2012): 38-46

Boehringer Ingelheim Pharmaceuticals. MEDICATION GUIDE: PRADAXA. Copyright 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022512s011mg.pdf Accessed 9/6/2012.

Bousser MG. Stroke prevention: an update. Frontiers of medicine. Mar 2012;6(1):22-34.

Brain Aneurysm Foundation (BAF). Understanding: Subarachnoid Hemorrhage. Available at:  http://www.bafound.org/subarachnoid-hemorrhage. Last updated 2011. Accessed 9/20/2012.

Brisman JL, Song JK, Newell DW. Cerebral aneurysms. The New England journal of medicine. Aug 31 2006;355(9):928-939.

Bronner LL, Kanter DS, Manson JE. Primary prevention of stroke. The New England journal of medicine. Nov 23 1995;333(21):1392-1400.

Brott T, Bogousslavsky J. Treatment of acute ischemic stroke. The New England journal of medicine. Sep 7 2000;343(10):710-722.

Buchner NJ, Sanner BM, Borgel J, Rump LC. Continuous positive airway pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. American journal of respiratory and critical care medicine. Dec 15 2007;176(12):1274-1280.

Casas JP, Shah T, Hingorani AD, et al. "C-reactive protein and coronary heart disease: a critical review." J.Intern.Med. 264(2008): 295-314.

Cassidy A, Rimm EB, O'Reilly EJ, et al. "Dietary flavonoids and risk of stroke in women." Stroke 43(2012): 946-951.

Choi HA, Ko SB, Chen H, et al. Acute effects of nimodipine on cerebral vasculature and brain metabolism in high grade subarachnoid hemorrhage patients. Neurocritical care. Jun 2012;16(3):363-367.

Chuang SY, Bai CH, Chen WH, et al. "Fibrinogen independently predicts the development of ischemic stroke in a Taiwanese population: CVDFACTS study." Stroke 40(2009): 1578-1584.

Cocho D, Belvis R, Marti-Fabregas J, et al. Reasons for exclusion from thrombolytic therapy following acute ischemic stroke. Neurology. Feb 22 2005;64(4):719-720.

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139 – 1151.

Das AM, Khan M. Obstructive sleep apnea and stroke. Expert review of cardiovascular therapy. Apr 2012;10(4):525-535.

Das RR, Seshadri S, Beiser AS, et al. "Prevalence and correlates of silent cerebral infarcts in the Framingham offspring study." Stroke 39(2008): 2929-2935

Davel AP, Wenceslau CF, Akamine EH, Xavier FE, Couto GK, Oliveira HT, Rossoni LV. Endothelial dysfunction in cardiovascular and endocrine-metabolic diseases: an update. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica ... [et al.]. Sep 2011;44(9):920-932.

Davis SM, Donnan GA. Clinical practice. Secondary prevention after ischemic stroke or transient ischemic attack. The New England journal of medicine. May 17 2012;366(20):1914-1922.

Dedoussis GV, Panagiotakos DB, Chrysohoou C, et al. Effect of interaction between adherence to a Mediterranean diet and the methylenetetrahydrofolate reductase 677C-->T mutation on homocysteine concentrations in healthy adults: the ATTICA Study. Am J Clin Nutr. 2004 Oct;80(4):849-54.

Dekanski D, Selakovic V, Piperski V, et al. "Protective effect of olive leaf extract on hippocampal injury induced by transient global cerebral ischemia and reperfusion in Mongolian gerbils." Phytomedicine. 18(2011): 1137-1143

Del Turco S, Bianchini E, Bucalo R, Basta G, Bruno RM, Sicari R. [Endothelial dysfunction. An integrated overview of the physiopatologic and diagnostic aspects]. Recenti progressi in medicina. Mar 2012;103(3):109-118.

Del Zoppo GJ, Saver JL, Jauch EC, Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke; a journal of cerebral circulation. Aug 2009;40(8):2945-2948.

Dey M, Jaffe J, Stadnik A, et al. "External ventricular drainage for intraventricular hemorrhage." Curr.Neurol.Neurosci.Rep. 12(2012): 24-33

Di Napoli M, Schwaninger M, Cappelli R, et al. “Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members.” Stroke. 36. 2005: 1316-1329.

Di Napoli NM, Papa F, Bocola V. "C-reactive protein in ischemic stroke: an independent prognostic factor." Stroke 32(2001): 917-924

Ding EL and Mozaffarian D. "Optimal dietary habits for the prevention of stroke." Semin.Neurol. 26(2006): 11-23.

Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke; a journal of cerebral circulation. Jun 2009;40(6):2276-2293.

El SN and Karakaya S. "Olive tree (Olea europaea) leaves: potential beneficial effects on human health." Nutr.Rev. 67(2009): 632-638

Elkind MSV. "Inflammatory mechanisms of stroke." Stroke 41(2010): S3-S8.

Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. The New England journal of medicine. Jun 26 2008;358(26):2765-2775.

Everett BM, Glynn RJ, MacFadyen JG, Ridker PM. Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Circulation. Jan 5 2010;121(1):143-150.

Felmeden DC, Spencer CG, Belgore FM, et al. "Endothelial damage and angiogenesis in hypertensive patients: relationship to cardiovascular risk factors and risk factor management." Am.J.Hypertens. 16(2003): 11-20.

Forbes CD. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination. ESPS Investigators. European Stroke Prevention Study. Thrombosis research. Sep 15 1998;92(1 Suppl 1):S1-6.

Francis J, Raghunathan S, Khanna P. The role of genetics in stroke. Postgraduate medical journal. Sep 2007;83(983):590-595.

Franco V, Oparil S,Carretero OA. "Hypertensive therapy: Part I." Circulation 109(2004): 2953-2958

Fujita M, Ohnishi K, Takaoka S, et al. "Antihypertensive effects of continuous oral administration of nattokinase and its fragments in spontaneously hypertensive rats." Biol.Pharm.Bull. 34(2011): 1696-1701

Fung TT, Rexrode KM, Mantzoros CS, et al. "Mediterranean diet and incidence of and mortality from coronary heart disease and stroke in women." Circulation 119(2009): 1093-1100

Furie K and Inzucchi SE. "Diabetes mellitus, insulin resistance, hyperglycemia, and stroke." Curr.Neurol.Neurosci.Rep. 8(2008): 12-19

Gardener H, Wright CB, Gu Y, et al. "Mediterranean-style diet and risk of ischemic stroke, myocardial infarction, and vascular death: the Northern Manhattan Study." Am.J.Clin.Nutr. 94(2011): 1458-1464

Geeganage CM, Diener HC, Algra A, et al. "Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials." Stroke 43(2012): 1058-1066

Holmes DR, Reddy VY, Turi ZG, et al. "Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial." Lancet 374(2009): 534-542

Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002 Oct 23-30;288(16):2015-22.

Houston MC. "The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease." Ther.Adv.Cardiovasc.Dis. 4(2010): 165-183

Huang T, Chen Y, Yang B, et al. "Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality." Clin.Nutr. (2012a)

Huang Y, Jing J, Zhao XQ, et al. "High-sensitivity C-reactive protein is a strong risk factor for death after acute ischemic stroke among Chinese." CNS.Neurosci.Ther. 18(2012b): 261-266

Huo Y, Qin X, Wang J, et al. "Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-analysis." Int.J Clin Pract. 66(2012): 544-551

Hyman DJ pavlik VN. Poor hypertension control: let’s stop blaming the patients. Cleve Clin J Med. 2002 Oct;69(10):793-9.

Jasuja R, Passam FH, Kennedy DR, et al. "Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents." J.Clin.Invest 122(2012): 2104-2113

Kaslow JE. Fibrinogen. Available at: http://www.drkaslow.com/html/fibrinogen.html. 2011.

Kastorini CM, Milionis HJ, Kantas D, et al. "Adherence to the Mediterranean Diet in Relation to Ischemic Stroke Nonfatal Events in Nonhypercholesterolemic and Hypercholesterolemic Participants: Results of a Case/Case-Control Study." Angiology (2011)

Kawano H, Yasue H, Kitagawa A, et al. "Dehydroepiandrosterone supplementation improves endothelial function and insulin sensitivity in men." J.Clin.Endocrinol.Metab 88(2003): 3190-3195.

Khaw AV, Kessler C. [Stroke: epidemiology, risk factors, and genetics]. Hamostaseologie. Nov 2006;26(4):287-297.

Kim JH, Park IS, Park KB, Kang DH, Hwang SH. Intraarterial nimodipine infusion to treat symptomatic cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Journal of Korean Neurosurgical Society. Sep 2009;46(3):239-244.

Kim JY, Gum SN, Paik JK, et al. "Effects of nattokinase on blood pressure: a randomized, controlled trial." Hypertens.Res. 31(2008): 1583-1588

Kojima G, Bell C, Abbott RD, et al. "Low Dietary Vitamin D Predicts 34-Year Incident Stroke: The Honolulu Heart Program." Stroke (2012)

Kokubo Y. "The mutual exacerbation of decreased kidney function and hypertension." J.Hypertens. 30(2012): 468-469

Kothari R, Sauerbeck L, Jauch E, Broderick J, Brott T, Khoury J, Liu T. Patients' awareness of stroke signs, symptoms, and risk factors. Stroke; a journal of cerebral circulation. Oct 1997;28(10):1871-1875.

Kreft L, Fabjan N, Yasumoto K. Rutin content in buckwheat (Fagopyrum esculentum Moench) food materials and products. Food Chemistry. 2006;98(3):508-512.

Lager KE, Wilson A, Khunti K, Mistri AK. Quality of secondary prevention measures in TIA patients: a retrospective cohort study. Postgraduate medical journal. Jun 2012;88(1040):305-311.

Lalancette-Hebert M, Julien C, Cordeau P, et al. "Accumulation of dietary docosahexaenoic acid in the brain attenuates acute immune response and development of postischemic neuronal damage." Stroke 42(2011): 2903-2909.

Lansberg MG, O'Donnell MJ, Khatri P, et al. "Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines." Chest 141(2012): e601S-e636S

Lata B, Trampczynska A, Paczesna J. Cultivar variation in apple peel and whole fruit phenolic composition. Scientia Horticulturae. 2009;121(2):176-181.

Lim JS, Kwon HM. Risk of "silent stroke" in patients older than 60 years: risk assessment and clinical perspectives. Clin Interv Aging. 2010 Sep 7;5:239-51.

Lip GY. "Can we predict stroke in atrial fibrillation?" Clin.Cardiol. 35 Suppl 1(2012): 21-27

Lopez-Minguez JR, Eldoayen-Gragera J, Gonzalez-Fernandez R, et al. Immediate and One-year Results in 35 Consecutive Patients After Closure of Left Atrial Appendage With the Amplatzer Cardiac Plug. Revista espanola de cardiologia. Aug 29 2012.

Lu KT, Chiou RY, Chen LG, et al. "Neuroprotective effects of resveratrol on cerebral ischemia-induced neuron loss mediated by free radical scavenging and cerebral blood flow elevation." J Agric.Food Chem. 54(2006): 3126-3131

Macdonald RL, Higashida RT, Keller E, et al. "Randomized trial of clazosentan in patients with aneurysmal subarachnoid hemorrhage undergoing endovascular coiling." Stroke 43(2012): 1463-1469.

Macdonald RL, Higashida RT, Keller E, et al. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet neurology. Jul 2011;10(7):618-625.

Mannucci PM. "Factor VIII inhibitors in previously treated hemophilic patients." J.Thromb.Haemost. 9(2011): 2328-2329.

Manolescu BN, Oprea E, Farcasanu IC, et al. "Homocysteine and vitamin therapy in stroke prevention and treatment: a review." Acta Biochim.Pol. 57(2010): 467-477.

Mansukhani MP, Bellolio MF, Kolla BP, Enduri S, Somers VK, Stead LG. Worse outcome after stroke in patients with obstructive sleep apnea: an observational cohort study. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. Sep-Oct 2011;20(5):401-405.

Masuda J, ka T, Notsu Y. Silent stroke: pathogenesis, genetic factors and clinical implications as a risk factor. Curr Opin Neurol. 2001 Feb;14(1):77-82.

Mayo Clinic. Aphasia. Available at: http://www.mayoclinic.com/health/aphasia/DS00685. 5/8/2012c. Accessed 9/24/2012.

Mayo Clinic. Stroke. Last updated 7/3/2012b. Available at: http://www.mayoclinic.com/health/stroke/DS00150/DSECTION=treatments-and-drugs Accessed 9/6/2012.

Merck Manual. Overview of Stroke. 11/2007. Available at: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/stroke_cva/overview_of_stroke.html Accessed 9/10/2012.

Miller J, Hartwell C, Lewandowski C. Stroke treatment using intravenous and intra-arterial tissue plasminogen activator. Current treatment options in cardiovascular medicine. Jun 2012;14(3):273-283.

Mitrou PN, Kipnis V, Thiebaut AC, et al. "Mediterranean dietary pattern and prediction of all-cause mortality in a US population: results from the NIH-AARP Diet and Health Study." Arch.Intern.Med. 167(2007): 2461-2468

Mozaffarian D and Wu JH. "Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events." J.Am.Coll.Cardiol. 58(2011): 2047-2067.

Murray JC, Kelly MA, Gorelick PB. Ticlopidine: a new antiplatelet agent for the secondary prevention of stroke. Clinical neuropharmacology. Feb 1994;17(1):23-31.

National Institute for Health and Clinical Excellence (NICE). "Stroke: Diagnosis and initial management of acute stroke and transient ischemic attack (TIA).” Available at:  http://publications.nice.org.uk/stroke-cg68. July 2008. Accessed July 27, 2012.

National Institute of Health (NIH). National Insitute on Aging. “Aging Hearts and Arteries: A Scientific Quest. Chapter 4: Blood Vessels and Aging: The Rest of the Journey.” Available at: http://www.nia.nih.gov/health/publication/aging-hearts-and-arteries-scientific-quest/chapter-4-blood-vessels-and-aging-rest. Last updated November 22, 2011. Accessed July 27, 2012.

National Stroke Association (NSA). “Spasticity and Paralysis.” Available at: http://www.stroke.org/site/PageServer?pagename=SPAST. Last updated May 2010. Accessed July 27, 2012.

National Stroke Association (NSA). “Stroke 101 Fact Sheet”. 2012e. Available at: http://www.stroke.org/site/DocServer/STROKE101_2009.pdf?docID=4541. Accessed 9/12/2012.

National Stroke Association (NSA). “Stroke Facts. Recovery After Stroke: Thinking and Cognition.” Available at:  http://www.stroke.org/site/DocServer/NSAFactSheet_Cognition.pdf?docID=986. Last updated June 2009b. Accessed July 27, 2012.  

National Stroke Association (NSA). “Types of Stroke.” Available at: http://www.stroke.org/site/PageServer?pagename=TYPE. 2012b. Accessed July 27, 2012.

National Stroke Association (NSA). “Vascular Dementia and Stroke.” Available at:  http://www.stroke.org/site/PageServer?pagename=VADEM. 2012c. Accessed July 27, 2012.

National Stroke Association (NSA). “Warning Signs of Stroke.” Available at: http://www.stroke.org/site/PageServer?pagename=SYMP. 2012a. Accessed July 27, 2012.

National Stroke Association (NSA). “What is a TIA?” Available at: http://www.stroke.org/site/PageServer?pagename=TIA. 2012d. Accessed 9/12/2012.     

National Stroke Association (NSA). 2009a “Stroke Facts. Hemorrhagic Stroke Fact Sheet.” Available at: http://www.stroke.org/site/DocServer/NSAFactSheet_HemorrhagicStroke_7-09.pdf?docID=3025. Accessed July 27, 2012.

National Stroke Association (NSA). Aphasia. Available at: http://www.stroke.org/site/PageServer?pagename=aphasia. Last updated August 2012g. Accessed September 21, 2012.

National Stroke Association (NSA). Pain. Availbale at: http://www.stroke.org/site/PageServer?pagename=pain. Last updated August 2012f. Accessed September 21, 2012.

Norrving B. Dipyridamole with aspirin for secondary stroke prevention. Lancet. May 20 2006;367(9523):1638-1639.

Norrving B. Long-term prognosis after lacunar infarction. Lancet neurology. Apr 2003;2(4):238-245.

Pappa T, Vemmos K, Saltiki K, Mantzou E, Stamatelopoulos K, Alevizaki M. Severity and outcome of acute stroke in women: relation to adrenal sex steroid levels. Metabolism: clinical and experimental. Jan 2012;61(1):84-91.

Park S and Lee BK. "Vitamin D deficiency is an independent risk factor for cardiovascular disease in Koreans aged >/= 50 years: results from the Korean National Health and Nutrition Examination Survey." Nutr.Res.Pract. 6(2012): 162-168

Parvizi J, Anderson SW, Martin CO, Damasio H, Damasio AR. Pathological laughter and crying: a link to the cerebellum. Brain : a journal of neurology. Sep 2001;124(Pt 9):1708-1719.

Patyar S, Prakash A, Modi M, et al. "Role of vinpocetine in cerebrovascular diseases." Pharmacol.Rep. 63(2011): 618-628

Pendlebury ST and Rothwell PM. "Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis." Lancet Neurol. 8(2009): 1006-1018

Perrinjaquet-Moccetti T, Busjahn A, Schmidlin C, et al. "Food supplementation with an olive (Olea europaea L.) leaf extract reduces blood pressure in borderline hypertensive monozygotic twins." Phytother.Res. 22(2008): 1239-1242

PubMed Health. Stroke. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001740/. Reviewed 6/24/2011. Accessed 9/28/2012.

PubMed Health. Stroke. Available at: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001740/. Reviewed 6/24/2011. Accessed 9/28/2012.

Pyorala M, Miettinen H, Halonen P, Laakso M, Pyorala K. Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. Arteriosclerosis, thrombosis, and vascular biology. Feb 2000;20(2):538-544.

Qureshi AI, Tuhrim S, Broderick JP, Batjer HH, Hondo H, Hanley DF. Spontaneous intracerebral hemorrhage. N Engl J Med. 2001 May 10;344(19):1450-60.

Rashid P, Leonardi-Bee J, Bath P. Blood pressure reduction and secondary prevention of stroke and other vascular events: a systematic review. Stroke; a journal of cerebral circulation. Nov 2003;34(11):2741-2748.

Reiffel JA, McDonald A. Antiarrhythmic effects of omega-3 fatty acids. The American journal of cardiology. Aug 21 2006;98(4A):50i-60i.

Reinhart KM, Coleman CI, Teevan C, et al. "Effects of garlic on blood pressure in patients with and without systolic hypertension: a meta-analysis." Ann Pharmacother. 42(2008): 1766-1771

Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics--2012 update: a report from the American Heart Association. Circulation. Jan 3 2012;125(1):e2-e220.

Rosen H. "Dextromethorphan/quinidine sulfate for pseudobulbar affect". Drugs Toxicity (Barc) 44(2008):661-8.

Roth JM. Recombinant tissue plasminogen activator for the treatment of acute ischemic stroke. Proceedings (Baylor University. Medical Center). Jul 2011;24(3):257-259.

Rothwell PM, Algra A,Amarenco P. "Medical treatment in acute and long-term secondary prevention after transient ischaemic attack and ischaemic stroke." Lancet 377(2011): 1681-1692

Ru San T, Chan MY, Wee Siong T, Kok Foo T, Kheng Siang N, Lee SH, Chi Keong C. Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis. 2012;2012:108983.

Rundek T, Gardener H, Xu Q, et al. "Insulin resistance and risk of ischemic stroke among nondiabetic individuals from the northern Manhattan study." Arch.Neurol. 67(2010): 1195-1200

Sabri M, Ai J, Macdonald RL. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan. Stroke; a journal of cerebral circulation. May 2011;42(5):1454-1460.

Sacco RL, Benjamin EJ, Broderick JP, et al. "American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors." Stroke 28(1997): 1507-1517

Sacco RL, Benson RT, Kargman DE, et al. "High-density lipoprotein cholesterol and ischemic stroke in the elderly: the Northern Manhattan Stroke Study." JAMA 285(2001): 2729-2735

Sahathevan R, Brodtmann A,Donnan GA. "Dementia, stroke, and vascular risk factors; a review." Int.J.Stroke 7(2012): 61-73

Saini M, Ikram K, Hilal S, Qiu A, Venketasubramanian N, Chen C. Silent Stroke: Not Listened to Rather Than Silent. Stroke. 2012 Sep 4.

Samieri C, Feart C, Proust-Lima C, et al. "Olive oil consumption, plasma oleic acid, and stroke incidence: the Three-City Study." Neurology 77(2011): 418-425

Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke; a journal of cerebral circulation. Apr 2009;40(4):1365-1372.

Schellinger PD, Jansen O, Fiebach JB, Hacke W, Sartor K. A standardized MRI stroke protocol: comparison with CT in hyperacute intracerebral hemorrhage. Stroke. 1999 Apr;30(4):765-8.

Schubert GA, Schilling L, Thome C. Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. Journal of neurosurgery. Dec 2008;109(6):1134-1140.

Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. The New England journal of medicine. Dec 10 2009;361(24):2342-2352.

Siguret V, Pautas E,Gouin-Thibault I. "Warfarin therapy: influence of pharmacogenetic and environmental factors on the anticoagulant response to warfarin." Vitam.Horm. 78(2008): 247-264

Singer P, Wirth M. Can n-3 PUFA reduce cardiac arrhythmias? Results of a clinical trial. Prostaglandins, leukotrienes, and essential fatty acids. Sep 2004;71(3):153-159.

Slark J, Bentley P, Majeed A, Sharma P. Awareness of stroke symptomatology and cardiovascular risk factors amongst stroke survivors. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. Jul 2012;21(5):358-362.

Spence JD and Stampfer MJ. "Understanding the complexity of homocysteine lowering with vitamins: the potential role of subgroup analyses." JAMA 306(2011): 2610-2611

Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. European Heart Journal. 2011;32(16):1968–1976.

Thethi I, Fareed J. Newer oral anticoagulants: a promising future. Clin. Appl. Thromb. Hemost. 2011;17(2):235.

van der Worp HB, van Gijn J. Clinical practice. Acute ischemic stroke. The New England journal of medicine. Aug 9 2007;357(6):572-579.

Vermeer SE, Longstreth WT, Jr., Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet neurology. Jul 2007;6(7):611-619.

Wainwright MS, Mannix MK, Brown J, et al. "L-carnitine reduces brain injury after hypoxia-ischemia in newborn rats." Pediatr.Res. 54(2003): 688-695

Wang C, Harris WS, Chung M, et al. "n-3 Fatty acids from fish or fish-oil supplements, but not alpha-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review." Am.J.Clin.Nutr. 84(2006): 5-17

Wang L, Jia J, Wu L. The relationship between cognitive impairment and cerebral blood flow changes after transient ischaemic attack. Neurol Res. 2013;35(6):580-5.

Washington State Dept. of Health. Stroke Education Toolkit. Available at: http://www.doh.wa.gov/Portals/1/Documents/2900/StrokeEducationToolkit.pdf Pub. 9/2012. Accessed 9/24/2012.

Witham MD, Nadir MA, Struthers AD. Effect of vitamin D on blood pressure: a systematic review and meta-analysis. Journal of hypertension. Oct 2009;27(10):1948-1954.

Woo D, Haverbusch M, Sekar P, et al. Effect of untreated hypertension on hemorrhagic stroke. Stroke; a journal of cerebral circulation. Jul 2004;35(7):1703-1708.

Xian Y, Liang L, Smith EE, et al. Risks of intracranial hemorrhage among patients with acute ischemic stroke receiving warfarin and treated with intravenous tissue plasminogen activator. JAMA: the journal of the American Medical Association. Jun 27 2012;307(24):2600-2608.

Yatsu FM, Shaltoni HM. Implications of silent strokes. Current atherosclerosis reports. Jul 2004;6(4):307-313.

Zerwic J, Hwang SY, Tucco L. Interpretation of symptoms and delay in seeking treatment by patients who have had a stroke: exploratory study. Heart & lung : the journal of critical care. Jan-Feb 2007;36(1):25-34.

Zhang R, Zhang H, Zhang Z, et al. "Neuroprotective Effects of Pre-Treament with l-Carnitine and Acetyl-l-Carnitine on Ischemic Injury In Vivo and In Vitro." Int.J.Mol.Sci. 13(2012): 2078-2090

Zhang W, Sun K, Chen J, et al. "High plasma homocysteine levels contribute to the risk of stroke recurrence and all-cause mortality in a large prospective stroke population." Clin.Sci.(Lond) 118(2010): 187-194.

https://www.lifeextension.com/Protocols/Heart-Circulatory/Stroke-Cerebrovascular-Disease/Page-01